Lactams
Medchemexpress LLC 1H-isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-iodo | 2509137-01-1 | MFCD31735039 | 98.0% | 384.13 | C13H9IN2O4 | 500 MG
Thalidomide-iodo is an iodinated derivative of thalidomide used as an E3 ligase (cereblon) activator for research applications. It is intended as a building block and synthetic intermediate for further derivatization by substitution of the iodine atom.
- E3 ligase activator (cereblon ligand) for targeted protein degradation research.
- Suitable as a synthetic intermediate for iodide substitution and further derivatization.
- High purity: 98.0% (NMR).
- Molecular formula C13H9IN2O4; molecular weight 384.13.
- CAS number 2509137-01-1.
- Appearance: gray to dark gray solid.
- Storage: 4°C, protect from light; in solvent: -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC Thalidomide-4-O-C9-NH2 (hydrochloride) | 99.3% | 451.94 | 25 MG
Thalidomide-4-O-C9-NH2 hydrochloride is a chemical compound for laboratory research and the manufacture of substances. This compound is stable under recommended storage conditions, which include sealed storage at -20°C, away from moisture and light. If in solvent, it can be stored at -80°C for 6 months or -20°C for 1 month.
- Intended for laboratory research and substance manufacturing
- Molecular weight of 451.94
- Purity of 99.26%
- Stable under recommended storage conditions
- Store at -20°C, sealed, away from moisture and light
- In solvent, store at -80°C for 6 months or -20°C for 1 month
- Can be shipped at room temperature if transit is less than 2 weeks
![Medchemexpress LLC 6H-Thieno[3,2-f]triazolo[4,3-a]diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, cyclopropyl ester, (6S)- | 3077900-08-1 | 98.3% | 440.95 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000384892-logo.png-250.jpg){kind=logo}
Medchemexpress LLC 6H-Thieno[3,2-f]triazolo[4,3-a]diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, cyclopropyl ester, (6S)- | 3077900-08-1 | 98.3% | 440.95 | 25 MG
DDL-357 is a potent secreted clusterin enhancer. It reduces phospho-tau in the brain and improves memory in the murine 3xTg-AD model. It is for research use only.
- Potent secreted clusterin enhancer.
- Reduces phospho-tau in the brain.
- Improves memory in the murine 3xTg-AD model.
Medchemexpress LLC (R)-Thalidomide | 2614-06-4 | 99.8% | 258.23 | 1 MG
(R)-Thalidomide, also known as (R)-(+)-Thalidomide, is the R-enantiomer of Thalidomide, possessing psychomotor stabilizing properties. It is intended for research use only and is not sold to patients.
- (R)-Thalidomide binds more strongly to the selective sites of MIP (molecularly imprinted polymer) compared to other forms, indicating distinct biological entities.
- In vivo studies in F344 rats with 9L gliosarcoma tumors showed that serum and tissue concentrations of (R)-thalidomide were 40-50% greater than those of (S)-thalidomide.
- Co-administration of BCNU or cisplatin with thalidomide did not alter the concentration enantioselectivity in rats.
![Medchemexpress LLC 5-[(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-isoindole-1,3-dione | 2357110-24-6 | MFCD34563706 | 98.0% | 311.29 g/mol | C16H13N3O4 | 50 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000284650.png-250.jpg)
Medchemexpress LLC 5-[(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-isoindole-1,3-dione | 2357110-24-6 | MFCD34563706 | 98.0% | 311.29 g/mol | C16H13N3O4 | 50 MG
Thalidomide-5-NH-C-alkyne is an E3 ligase ligand-linker conjugate that contains a terminal alkyne for bioorthogonal conjugation. It is provided as a small-quantity research reagent intended for PROTAC development and target protein conjugation. Reported properties include a molecular formula of C16H13N3O4, a molecular weight of 311.29 g/mol, and a reported purity of 98.0%.
- Contains an E3 ligase ligand with a terminal alkyne for conjugation.
- Designed for PROTAC development and target protein degradation studies.
- Reported purity 98.0% suitable for research applications.
- Provided as a small-quantity reagent (50 mg) for synthetic chemistry workflows.
- Molecular formula C16H13N3O4; molecular weight 311.29 g/mol.
- Store and handle according to supplier safety data sheet recommendations.
Medchemexpress LLC Thalidomide-pyrrolidine hydrochloride | 2616553-35-4 | 98.0% | 335.74 | C15H14ClN3O4 | 5 MG
Thalidomide-pyrrolidine hydrochloride is a cereblon-binding E3 ligase ligand supplied as the hydrochloride salt for use as a building block in PROTAC synthesis and targeted protein degradation research. It is intended for research use and is accompanied by quality documentation.
- Cereblon-binding E3 ligase ligand for PROTAC synthesis.
- Hydrochloride salt form for handling and stability.
- High purity: 98.0%.
- Documented quality: data sheet, certificate of analysis, and safety data sheet available.
- Storage recommendations: store dry at room temperature; in solvent, -80°C (2 years) or -20°C (1 year).
Medchemexpress LLC α-MSH (α-Melanocyte-Stimulating Hormone) | 581-05-5 | 99.9% | 1664.88 | 5 MG
α-MSH (α-Melanocyte-Stimulating Hormone) | 581-05-5 | 99.9% | 1664.88 | 5 MG
Cayman Chemical ThalIdomIde 5mg
An active enantiomer of (±)-thalidomide; enhances TPA-induced TNF-α production in HL-60 cells from 0.1-100 µM; preincubation of isolated RIR chicken donor blood reduces recipient chicken embryo splenomegaly in a model of graft versus host disease at 10 mg/ml; induces fetal malformations when administered to pregnant female rabbits at 150 mg/kg
Medchemexpress LLC Thalidomide-O-amido-C4-NH2 (TFA) | 1799711-25-3 | MFCD31560484 | 99.9% | 516.42 g/mol | C21H23F3N4O8 | 1 G
Thalidomide-O-amido-C4-NH2 (TFA) is a thalidomide-derived cereblon ligand supplied as the trifluoroacetate salt and intended as a building block for E3 ligase ligand-linker conjugates and PROTAC research. The compound is provided as a solid research reagent with characterized purity, formula, and solubility data for in vitro and in vivo formulation.
- Intended for research use only.
- High purity 99.92%.
- Molecular weight 516.42 g/mol.
- Molecular formula C21H23F3N4O8.
- Soluble in DMSO (~42.86 mg/mL); multiple in vivo formulation protocols reported.
- Store dry at 4°C; in solvent store at -80°C for up to 6 months.
Medchemexpress LLC Thalidomide-5-PEG4-NH2 hydrochloride | 2743434-24-2 | 95.2% | 485.92 g/mol | C21H28ClN3O8 | 5 MG
Thalidomide-5-PEG4-NH2 hydrochloride is a thalidomide-derived E3 ligase ligand-linker conjugate that combines a cereblon-binding thalidomide moiety with a four-unit PEG linker. It is intended as a research reagent for PROTAC design and targeted protein degradation studies and is supplied as a light yellow to yellow oil with reported high purity.
- Designed as an E3 ligase ligand-linker conjugate for PROTAC synthesis.
- Contains a cereblon-binding thalidomide moiety with a PEG4 linker for linker flexibility.
- High reported purity suitable for research applications (95.2%).
- Soluble in DMSO at 100 mg/mL; ultrasonic agitation recommended.
- Light yellow to yellow oil; easy to handle in synthetic workflows.
- Store sealed away from moisture; recommended storage at -20°C (in solvent: -80°C for long term).
Medchemexpress LLC Thalidomide-O-amido-PEG2-C2-NH2 (TFA) | 1957235-75-4 | 576.48 | 50 MG
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and a 2-unit PEG linker used in PROTAC technology. This product is intended for research use only and for experienced personnel in appropriately equipped facilities.
- Incorporates Thalidomide-based cereblon ligand
- Features a 2-unit PEG linker
- Used in PROTAC technology
- PROTACs exploit the intracellular ubiquitin-proteasome system
- Selectively degrades target proteins
- Identified as laboratory chemicals for substance manufacture
Medchemexpress LLC Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride | 2376990-30-4 | 498.91 | 50 MG
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, and can be an immunomodulator for the treatment of cancer. PROTACs, which contain two different ligands connected by a linker (one for an E3 ubiquitin ligase and the other for the target protein), exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
- Incorporates an E3 ligase ligand and a linker.
- Can be an immunomodulator for the treatment of cancer.
- Exploits the intracellular ubiquitin-proteasome system.
- Selectively degrades target proteins.
- For research use only.